Sino Biopharmaceutical, One of the Largest Chinese Drugmakers, Is in the Transformation Stage
Sino Biopharm has a good financial position. As of December 2024, it has CNY 9.6 billion in cash on hand and CNY 9.6 billion in debt. Total debt outstanding is 14.7% of its total assets. Its capital ...
BioSpace1d
J&J Wins Crohn’s Expansion for Tremfya as Stelara Biosimilars Enter US Market
The label expansion couls help J&J establish Tremfya as a successor to Stelara, which is now facing a growing biosimilar ...
Pharmabiz1d
Alvotech acquires Xbrane’s R&D operations in Sweden and further affirms its global leadership position in biosimilars development and production
Reykjavik, Iceland Friday, March 21, 2025, 12:00 Hrs [IST] ...
The Chosun Ilbo on MSN2d
Korean biotech firms race into $26 billion U.S. biosimilar market
South Korean biotech firms are targeting the $26 billion biosimilar market opening up as patents expire on more than 10 ...
Fierce Pharma2d
J&J advances Stelara succession scheme with FDA nod for Tremfya in Crohn's disease
With another inflammatory bowel disease (IBD) approval in the bag for Tremfya, Johnson & Johnson continues to make good on ...
MedPage Today2d
Will Medicare Price Negotiations Really Cut Rheum Drug Costs?
Talks between CMS and drugmaker Amgen authorized under the Inflation Reduction Act (IRA), former President Biden's signature ...
Capacity push and new drugs critical for Aurobindo's health
A delay in drug approvals in the US market remains a concern for Aurobindo. The company stated that eight ANDAs (abbreviated ...
Targeted Oncology3d
FDA Grants Orphan Drug Designation to HLX22 for Gastric Cancer Treatment
The FDA granted orphan drug designation to HLX22 for gastric cancer, advancing global phase 3 trials to improve first-line ...
Zacks Investment Research on MSN3d
FDA Accepts RDY & ALVO's Prolia & Xgeva Biosimilar BLA for Review
Dr. Reddy’s Laboratories RDY and partner, Alvotech ALVO, announced the FDA’s acceptance of a regulatory filing, seeking the ...
Chosunbiz4d
Samsung Biologics, Hanmi Pharmaceutical Partner to Sell Prolia Biosimilar in Korea
Samsung Biologics, Hanmi Pharmaceutical Partner to Sell Prolia Biosimilar in Korea Samsung Bioepis and Hanmi Pharmaceutical ...
Alvotech and Dr. Reddy’s gets FDA nod for Biologic License Application for AVT03
Dr. Reddy’s Laboratories (RDY) and Alvotech (ALVO) announced that the U.S. FDA has accepted a Biologic License Application submission for AVT03. Read more here.
Alvotech and Dr. Reddy’s Announce FDA acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®
“The FDA's filing acceptance of Dr. Reddy's proposed denosumab biosimilar marks an important milestone in bringing this biosimilar medication to more patients throughout the U.S.,” said Milan ...